Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. Reply

Sander F. Garrelfs, John M. Gansner, John C. Lieske

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)e69
JournalThe New England journal of medicine
Volume385
Issue number20
DOIs
StatePublished - Nov 11 2021

ASJC Scopus subject areas

  • Medicine(all)

Cite this